Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
Score 1
2015 pubmed 50 citations

Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction.

Sanna. M Germana MG; Vincent. Kevin P KP; Repetto. Emanuela E; Nguyen. Nhan N; Brown. Steven J SJ; Abgaryan. Lusine L; Riley. Sean W SW; Leaf. Nora B NB; Cahalan. Stuart M SM; Kiosses. William B WB; Kohno. Yasushi Y; Brown. Joan Heller JH; McCulloch. Andrew D AD; Rosen. Hugh H; Gonzalez-Cabrera. Pedro J PJ

Key Findings

  • S1P3 activation can cause sinus bradycardia and complete heart block in mice.
  • Blocking S1P3 with the antagonist SPM-354 restores normal heart rhythm and reverses bradycardia.
  • S1P3 is highly expressed in the atrioventricular node and His-Purkinje fibers, indicating a direct role in cardiac conduction.

Practical Outcomes

  • For now, this research is limited to mouse models and does not provide a usable protocol for humans. It suggests that drugs targeting S1P3 could one day help treat heart rhythm disorders, but there is no immediate actionable advice for biohackers or self‑experimenters.

Summary

Scientists discovered that a protein called S1P3 helps control the heart's rhythm in mice. When they activated S1P3, the mice sometimes developed dangerous slow heartbeats or even complete heart block. A new drug that blocks S1P3 (SPM-354) was able to fix these problems, showing that S1P3 is a key player in keeping the heart beating normally.

Abstract

The molecular pharmacology of the G protein-coupled receptors for sphingosine 1-phosphate (S1P) provides important insight into established and new therapeutic targets. A new, potent bitopic S1P3 antagonist, SPM-354, with in vivo activity, has been used, together with S1P3-knockin and S1P3-knockout mice to define the spatial and functional properties of S1P3 in regulating cardiac conduction. We show that S1P3 is a key direct regulator of cardiac rhythm both in vivo and in isolated perfused hearts. 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in vivo and S1P in isolated hearts induced a spectrum of cardiac effects, ranging from sinus bradycardia to complete heart block, as measured by a surface electrocardiogram in anesthetized mice and in volume-conducted Langendorff preparations. The agonist effects on complete heart block are absent in S1P3-knockout mice and are reversed in wild-type mice with SPM-354, as characterized and described here. Homologous knockin of S1P3-mCherry is fully functional pharmacologically and is strongly expressed by immunohistochemistry confocal microscopy in Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4 (HCN4)-positive atrioventricular node and His-Purkinje fibers, with relative less expression in the HCN4-positive sinoatrial node. In Langendorff studies, at constant pressure, SPM-354 restored sinus rhythm in S1P-induced complete heart block and fully reversed S1P-mediated bradycardia. S1P3 distribution and function in the mouse ventricular cardiac conduction system suggest a direct mechanism for heart block risk that should be further studied in humans. A richer understanding of receptor and ligand usage in the pacemaker cells of the cardiac system is likely to be useful in understanding ventricular conduction in health, disease, and pharmacology.

Study Information

Provider

pubmed

Year

2015

Date

2015-10-22T00:00:00.000Z

DOI

10.1124/mol.115.100222

Citations

50

References

47